US FDA's Oncology Center of Excellence has coined the term "dangling accelerated approvals" when confirmatory trials fail to verify clinical benefit but indications remain on the label. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
